Results 81 to 90 of about 1,087 (181)

Exploring the Potential Role of CYP2C19 Genetic Variability in Cenobamate Treatment

Applied Sciences
Background: Cenobamate is a novel antiseizure medication with potential interactions involving cytochrome P450 enzymes, including CYP2C19. Genetic variability in CYP2C19 may influence drug metabolism and tolerability, although its clinical relevance in ...
Giovanni Falcicchio, Valeria Delmonte, Teresa Francavilla, Alessandro Introna, Maria Addolorata Mariggiò, Mariella Pafundi, Mirko Perrone, Angela Vinella, Emilio Russo   +8 more
doaj   +1 more source

The Theoretical Description for Cenobamate CuS-Assisted Electrochemical Determination in Pharmaceutical Formulations and Wastewater

Orbital: The Electronic Journal of Chemistry
For the first time, the theoretical description for cenobamate antiepileptic drug on anode, assisted by copper sulfide nanoparticles in alkaline medium, has been given. Two mechanisms, involving either tetrazolic ring, or the carbocyclic aromatic moiety,
Volodymyr Tkach, Tetiana Morozova, Viktoriia Khrutba, Andrii Hlukhonets, Marta Kushnir, Yana Ivanushko, Viktor Kryvetskyi, Inna Kryvetska, Igor Kryvetskyi, Petro Yagodynets, Mykhailo Kucher, Zholt Kormosh, Nadiia Chikun, Maria João Monteiro   +13 more
doaj   +1 more source

Potential of cenobamate as a broad-spectrum antiseizure medication

Expert Opinion on Pharmacotherapy
The process of diagnosing patients with epilepsy and selecting the optimal drug remains a significant challenge. Broad-spectrum antiseizure medications (ASMs) treat focal and generalized seizures without worsening other seizure types, making them the drug of choice when the exact seizure classification for patients is unknown.
Susan M, Melnick, Sunita N, Misra, Marc, Kamin, Louis, Ferrari, Kelli J, Glenn   +4 more
openaire   +2 more sources

Cenobamate Monotherapy for Focal Epilepsy

Neurology Clinical Practice
BACKGROUND AND OBJECTIVES: Cenobamate is a novel antiseizure medication (ASM) approved by the Food and Drug Administration for use as adjunctive therapy in focal epilepsy. However, there are limited data on its use as a standalone monotherapy. The aim of our study was to investigate the use of cenobamate monotherapy and evaluate its clinical efficacy ...
Zengin, Erkam, Erol, Ferhat, Gil Guevara, Andrea, Lado, Fred Alexander   +3 more
openaire   +4 more sources

Cenobamate [PDF]

, 2022
openaire   +1 more source

Quantitative Analysis of Cenobamate and Concomitant Anti-Seizure Medications in Human Plasma via Ultra-High Performance Liquid Chromatography–Tandem Mass Spectrometry

Molecules
Cenobamate (CNB) is a new anti-seizure medication (ASM) recently introduced in clinical practice after approval by the FDA and EMA for the add-on treatment of focal onset seizures in adult patients.
Linda Molteni, Bruno Charlier, Albino Coglianese, Viviana Izzo, Giovanni Assenza, Pierantonio Menna, Ugo de Grazia, Annachiara D’Urso   +7 more
doaj   +1 more source

Cenobamate in adult patients with epilepsy and intellectual disability

Seizure: European Journal of Epilepsy
In people with intellectual disability (ID), prevalence of epilepsy is up to 50-times higher than in the general population and often difficult to treat. Multiple randomized controlled, observational and retrospective studies have demonstrated favorable efficacy of adjunctive cenobamate (CNB).
David Steinbart, Rebekka Geelhaar, Rebekka Lehmann, Anja Grimmer, Martin Holtkamp   +4 more
openaire   +2 more sources

Real-world safety comparison between cenobamate and lacosamide: a pharmacovigilance study based on the FDA Adverse Event Reporting System

Frontiers in Neurology
BackgroundCenobamate (CNB) and lacosamide (LCM) are two common used third-generation anti-seizure medications (ASMs) for third-line treatment of the drug-resistant epilepsy.
Shenglan Shang, Shenglan Shang, Dongxin Chen, Zhirui Song, Chengrui Zhou, Qiuyue Chang, Lu Xiang, Mengchen Yu, Yan Zhao, Weiliang Li, Fan Zhou, Airong Yu   +11 more
doaj   +1 more source

Early sedation-related adverse events with the cenobamate–clobazam combination in drug-resistant epilepsy: real-world preliminary observations

Background: Cenobamate is increasingly used as adjunctive treatment in adults with drug-resistant focal epilepsy. In clinical practice, the combination with clobazam is common and sedation-related adverse events (SRAEs) have been reported.
Vinella, Angela, Delmonte, Valeria, Perrone, Mirko, Francavilla, Teresa, Introna, Alessandro, Pafundi, Mariella, Russo, Emilio, Falcicchio, Giovanni, Mariggiò, Maria Addolorata   +8 more
core   +1 more source

Cenobamate for the Treatment of Focal Seizures [PDF]

US Neurology, 2020
William E Rosenfeld, Louis Ferrari, Pavel Klein   +2 more
openaire   +1 more source